The US has opened the floodgates to cheaper versions of biologic medicines, and analysts predict that by 2020,...
Up To Date
Backgrounds & Stories
Amgen’s Imlygic was approved last year – a move that finally added oncolytic viruses (OVs) to the healthcare...
Early January saw a few indicators that stock markets might deliver some solid biotech results in 2016, even...
Share
